coronavirus update indiaas on : 22 September 2020 06:08 GMT+5:30
COVID-19 Updates: Delhi,Maharashtra Among 5 States To Receive First Batch Of Drug
This morning, India, the fourth worst hit nation by the coronavirus, reported a total of 4.73 lakh infections and 14,894 deaths.
COVID-19 Updates: Delhi, Maharashtra Among 5 States To Receive First Batch Of Drug
New Delhi: Hetero Hyderabad-based drugmaker, which has the approval to manufacture and market the generic version of the experimental COVID-19 drug Remdesivir,has sent 20,000 vials to five states including Delhi and Maharashtra the two worst-affected states in the country.
Also, Tamil Nadu and Gujarat are the other two states that will receive the first batch of the drug which is being marketed under the brand name COVIFOR in India.Telangana's capital Hyderabad, where the drugmaker is based, will also receive the first consignment.
The Hetero has set a target to produce one lakh vials of the drug in two-three weeks.
The next batch of the drug will be shipped to Kolkata, Indore, Bhopal, Lucknow, Patna, Bhubaneshwar, Ranchi, Vijayawada, Kochi, Trivandrum, and Goa.
The drug currently is being manufactured at the company's formulation facility in Hyderabad. The active pharmaceutical ingredient(API) is being made in the firm's Visakhapatnam facility, reported news agency PTI.
The drug will be available only through hospitals and the government and not via retail, reported PTI quoting Hetero Group of Companies MD Vamsi Krishna Bandi.
"Backed by strong backward integration capabilities, we can ensure that the product is immediately made available to patients across the country," Mr. Bandi told PTI.
As per the reports, a patient will need at least six vials of the drug which will be used for the restricted emergency in severe coronavirus cases. Hetero said 100-milligram vial of the drug will cost Rs5,400.
The drugmaker Cipla has also signed a licensing agreement with the US-based Gilead Science Inche original manufacturer of Remdesivir - to make and sell the drug. Cipla has said its antiviral drug Remdesivir would be priced below Rs 5,000.
Regulator Drug Controller General of India (DCGI) has approved the generic versions made by Cipla and Hetero for restricted emergency use in severe COVID-19 cases.
The treatment was the first to show improvement in the trails on coronavirus patients who have won approval for emergency use in the severely ill patients in the United States and South Korea and received full approval in Japan. It is yet to be priced in the United States.
In India, the total number of coronavirus cases climbed to 4,73,105 and the death toll rises to 14,894 today, as per the data of Union Health Ministry. The country has reported 418 fatalities and a record single-day spike of 16,922 cases in the last 24 hours.